Mylan, Cephalon form agreements for pain, CNS disorder drugs

By Angela McDaniels

Seattle, Jan. 11 - Mylan Laboratories Inc. said its subsidiary Mylan Technologies Inc. has formed two strategic agreements with Cephalon Inc. for the use of Mylan Technologies' transdermal technology.

Cephalon will develop and commercialize branded transdermal products for the treatment of pain and central nervous system disorders. Mylan will receive milestone payments and ongoing royalties based on net sales of the products.

Further details were not disclosed.

"This type of collaboration will leverage Mylan Technologies' state-of-the-art technology and expertise and has the potential to allow Mylan to participate in branded commercial opportunities without additional research and development net costs," Mylan vice chairman and chief executive officer Robert J. Coury said in a company news release.

"These agreements are the latest in what we believe will be a series of branded strategic alliances and further demonstrate Mylan Technologies' position as partner of choice for transdermal technology," Coury added.

Mylan is a pharmaceutical company based in Pittsburgh that, through three principal subsidiaries, develops, licenses, manufactures and markets generic and proprietary products.

Cephalon is a biopharmaceutical company based in Frazer, Pa., that specializes in developing drugs to treat and manage neurological diseases, sleep disorders, cancer and pain.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.